Medtronic CEO Martha on beating estimates in Q1: Driven by growth across many of our businesses

Summary

Medtronic CEO Geoff Martha discussed the company's Q1 beat and attributed it to broad growth across businesses and newer growth drivers such as AFib ablation, robotics, and hypertension. He argued innovation is outpacing macro headwinds and expanding patient volumes in medtech. He also highlighted a ramp in tuck-in M&A, including the Cornerstone Robotics investment, which has roughly doubled Medtronic's total innovation investment.

• Medtronic shares rose after a Q1 top and bottom line beat and the announcement of a $700 million investment in Cornerstone Robotics.
• CEO Geoff Martha said the record quarter was driven by cardiac rhythm management, spine, AFib ablation, robotics, and hypertension.
• He said tariff, inflation, supply-chain, and cyber concerns are built into guidance but innovation is outpacing them.
• New AFib ablation and pacemaker innovation is lowering treatment thresholds and expanding the medtech patient pool.
• Medtronic has ramped tuck-in M&A in earlier-stage, high-growth areas over the past two years.
• The M&A push and organic R&D have roughly doubled Medtronic's total innovation investment.
• The CEO also detailed cybersecurity investments, employee training, and government information-sharing.